首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 非專利藥 > 生技仿製藥以及後發生物製劑:全球市場前景（2010∼2025年）
產業/市場分類
製藥 (4816)
肥胖症治療 (44)
非專利藥 (129)
疫苗 (181)
神經疾病 (172)
骨頭疾病治療 (37)
動物用醫藥 (17)
處方藥 (156)
規章 (126)
感染疾病 (346)
精神病 (84)
製藥企業 (524)
糖尿病 (191)
癌症 (909)
藥物開發 (1449)
DDS (182)
OTC 非處方藥 (150)
市場調查報告書

生技仿製藥以及後發生物製劑:全球市場前景（2010∼2025年）

Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - opportunities and challenges in this emerging market with high potential

出版商 Visiongain
出版日期 2010年05月 商品編碼 123491
內容資訊 英文 139 Pages
價格
US $ 2331 PDF by E-mail (Single User License)
US $ 4663 PDF by E-mail (Departmental License)
US $ 7772 PDF by E-mail (Site License)
US $ 10882 PDF by E-mail (Global Site License)


生技仿製藥以及後發生物製劑:全球市場前景（2010∼2025年） 是由出版商Visiongain在2010年05月所出版的。 這份英文市場調查報告書包含139 Pages 價格從美金2331起跳。

簡介

本報告書提供生物仿製藥以及後發生物製劑（Follow-On Biologics）之現狀與將來可能性的相關情報，其中包含研究開發動向與市場SWOT分析、2025年為止的市場發展預測等，概述如下。

第1章 總綱

第2章 生物仿製藥摘要

  • 生物科技與生物製劑
  • 生物製劑種類
  • 生物仿製藥、生物副廠藥、後續蛋白質產品

第3章 全球生物仿製藥市場：2010∼2025年

  • 全球生物製劑市場
  • 2009年生物仿製藥市場
  • 全球生物仿製藥市場銷售量預測：2010∼2025年
  • 單克隆抗體與抗炎症融合蛋白質
  • 胰島素
  • 促紅細胞生成素
  • 干擾素
  • 集落刺激因子與白細胞介素
  • 成長荷爾蒙

第4章 生物仿製藥業界以及對市場造成影響的課題

  • 生物仿製藥業界以及市場SWOT分析
  • 昂貴的生物製劑
  • 多數生物製劑很快或者已經專利期滿
  • 生物仿製藥開發上的課題
  • 建購生物仿製藥的認可規範
  • 歐洲的生物仿製藥導覽
  • 美國邁向後發生物製劑規制路徑開發的進步
  • 日本的生物仿製藥規範
  • 生物仿製藥的開發與行銷的經濟性

第5章 專家對該部門的見解

第6章 各地區生物仿製藥市場

  • 主要生物製劑的各國市場：2009年
  • 亞洲的地位
  • 各地區生物仿製藥市場：銷售量預測（2010∼2025年）
  • EU生物仿製藥市場
  • 美國生物仿製藥市場
  • 日本生物仿製藥市場

第7章 生物仿製藥研究開發管道

  • 生物仿製藥研究開發管道的競爭環境

第8章 結論

圖表

目錄

Abstract

In 2009, the biological (biologic) drug market generated over $125bn in revenues worldwide. There is great demand for lower-cost biological drugs. Commercial and regulatory developments will make biosimilars and follow-on biologics seize market share - our new report explains how. Many biologic patents will expire during our forecast period. There is mounting pressure from governments, insurers and patients' groups to reduce drug costs. Biologic drugs - noted as some of the most-expensive medicines - are prime targets. Developments facilitating biosimilars/follow-on biologics are gaining momentum, with commercial opportunities for the taking. The potential revenues are significant.

Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 will provide you with information that you need to understand current trends and future possibilities for those drugs. This report predicts how the biosimilars market will develop from 2010 onwards. We discuss the biosimilar/follow-on drugs and manufacturers most likely to achieve success in coming years.

Biologic drug classes covered in this report include:

  • Monoclonal antibodies
  • Fusion proteins
  • Erythropoietin
  • Growth hormones
  • Insulin products
  • Colony stimulating factors and interleukin-2 drugs
  • Interferons

We discuss prospects for each class, with biosimilar/follow-on targets identified and market forecasts to 2025 provided, along with supporting information.

Comprehensive analysis of the biosimilars/follow-on biologics sector

Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 examines that sector through a comprehensive review of information sources. We use primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are over 70 tables and figures included, as well as four interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025

This report gives you the following benefits in particular:

  • You will receive forecasts for the global biosimilar/follow-on biologics market, leading drug types and regional markets
  • You will identify biologic drugs with potential for biosimilar development
  • You will examine the driving forces, restraints, competition and opportunities facing participants in the biologic and biosimilar sectors
  • You will receive analysis of biosimilar legislation and regulatory guidance in the US, Europe and Japan - with existing and emerging trends discussed
  • You will investigate R&D developments in that sector, with up-and-coming trends highlighted
  • You will examine prospects for leading companies
  • You will discover interviews with experts regarding the present and future of the sector
  • You will find out how the biosimilars sector is progressing worldwide - technologically and commercially - and what the future holds.

You can obtain this report today

Nobody with an interest in the biological or blockbuster drug sectors should overlook our new study. We predict upheaval in the market for biotechnological drugs in the years ahead, as biologicals face increasing competition. This report provides information to help you benefit from that changing market. Do you want to harness those opportunities? You can stay ahead by ordering this report today.

Table of Contents

1. Executive Summary

  • 1.1 Biosimilars and Follow-On Biologics: Market Review
  • 1.2 Aims, Methods and Format of the Report

2. Introduction to Biosimilars

  • 2.1 Biotechnology and Biologic Drugs
  • 2.2 Types of Biologic Drugs
  • 2.3 Biosimilars, Biogenerics and ' Follow-On Protein Products'

3. The World Biosimilars Market, 2010-2025

  • 3.1 World Biologic Drug Market
    • 3.1.1 Leading Biologic Drug Types, 2009
    • 3.1.2 The Blockbuster Biologics
  • 3.2 The Biosimilar Market in 2009
  • 3.3 World Biosimilar Market: Sales Forecast, 2010-2025
    • 3.3.1 Biologics Will Continue to Outperform Small-Molecules
    • 3.3.2 Biosimilar Market Comes of Age: World Market Sales Forecast, 2010-2015
    • 3.3.3 World Biosimilar Market: Sales Forecast, 2015-2025
  • 3.4 Monoclonal Antibodies and Anti-Inflammatory Fusion Proteins (AIFPs)
    • 3.4.1 The Monoclonal Antibodies + AIFP Market, 2009
    • 3.4.2 Monoclonal Antibodies + AIFP Market: Further Growth from 2010-2025
    • 3.4.3 Reditux (Dr. Reddy' s): The World' s First Biosimilar Monoclonal Antibody
    • 3.4.4 Biosimilar Monoclonal Antibodies + AIFPs, 2010-2015
    • 3.4.5 Biosimilar Monoclonal Antibodies Take Off, 2015-2020
    • 3.4.6 Biosimilar Monoclonal Antibodies + AIFPs, 2020-2025
  • 3.5 Insulin
    • 3.5.1 The Branded Insulin Market, 2009
    • 3.5.2 The Biosimilar Insulin Market, 2008
    • 3.5.3 Gensulin/SciLin (Bioton/SciGen)
    • 3.5.4 Insugen (Biocon)
    • 3.5.5 Global Diabetes Increases Will Drive Insulin Market from 2010-2025
    • 3.5.6 Branded Insulin Market: Sales Forecast, 2010-2025
    • 3.5.7 Rapid Biosimilar Insulin Growth, 2010-2015
    • 3.5.8 Biosimilar Insulin Market: Sales Forecast, 2015-2025
  • 3.6 Erythropoietin
    • 3.6.1 The Branded Erythropoietin Market, 2009
    • 3.6.2 The Biosimilar Erythropoietin Market, 2009
    • 3.6.3 Binocrit/Epoetin Alfa Hexal/Abseamed (Sandoz/Medice)
    • 3.6.4 Silapo/Retacrit (Stada/Hospira)
    • 3.6.5 The Erythropoietin Market 2010-2025: Branded Drugs Facing Increasing Biosimilar Competition
    • 3.6.6 Biosimilar Erythropoietin Market: Sales Forecast, 2010-2015
    • 3.6.7 Favourable Long-Term Outlook for Biosimilar Erythropoietin, 2015-2025
  • 3.7 Interferons
    • 3.7.1 The Branded Interferon Market, 2009
    • 3.7.2 The Biosimilar Interferon Market, 2009
    • 3.7.3 Interferon Market Outlook, 2010-2025
    • 3.7.4 Biosimilar Interferon Market: Sales Forecast, 2010-2015
    • 3.7.5 Biosimilar Interferon Market: Sales Forecast, 2015-2025
  • 3.8 Colony Stimulating Factors (CSF) and Interleukin-2 (IL-2)
    • 3.8.1 The Branded CSF and IL-2 Drug Market, 2009
    • 3.8.2 The Biosimilar CSF and IL-2 Drug Market, 2009
    • 3.8.3 The CSF and IL-2 Drug Market, 2010-2025
    • 3.8.4 Biosimilar CSF and IL-2 Drugs Market: Sales Forecast, 2010-2015
    • 3.8.5 Biosimilar CSF and IL-2 Drugs Market: Sales Forecast, 2015-2025
  • 3.9 Growth Hormones
    • 3.9.1 The Branded Growth Hormone Market, 2009
    • 3.9.2 The Biosimilar Growth Hormone Market, 2009
    • 3.9.3 Omnitrope
    • 3.9.4 Eutropin
    • 3.9.5 Growth Hormone Market Outlook, 2010-2025
    • 3.9.6 Branded Growth Hormone Market: Sales Forecast, 2010-2025
    • 3.9.7 Biosimilar Growth Hormone Market: Sales Forecast, 2010-2015
    • 3.9.8 Long Term Prospects for Biosimilar Growth Hormones, 2015-2025

4. Issues Affecting the Biosimilars Industry and Market

  • 4.1 SWOT Analysis for the Biosimilar Industry and Market
  • 4.2 Biological Medicines are Expensive
  • 4.3 Many Biological Drugs have Expired or Soon-to-Expire Patents
  • 4.4 Challenges in Developing Biosimilar Drugs
    • 4.4.1 Biosimilars Not Developed with Ease of Traditional Generics
    • 4.4.2 Biologics are Large, Complex Molecules
    • 4.4.3 Complex Manufacturing Processes
    • 4.4.4 Biologic Drugs are Heterogeneous
    • 4.4.5 Biologic Drugs Difficult to Characterise & Slight Differences Have Important Clinical Consequences
    • 4.4.6 Biologic Drugs Have Potential for Immunogenicity
  • 4.5 Development of Regulations for the Approval of Biosimilars
    • 4.5.1 Key Issues for Development of Biosimilar Regulations
    • 4.5.2 Requirements for Clinical Trials
    • 4.5.3 Debate over Clinical Trial Requirements in the US
    • 4.5.4 Data Exclusivity Period
    • 4.5.5 Biosimilar Substitution
    • 4.5.6 International Non-Proprietary Names (INNs)
  • 4.6 European Biosimilar Guidelines
    • 4.6.1 EMEA Guidelines for Biosimilar Medicines
    • 4.6.2 Testing Requirements
    • 4.6.3 Clinical Testing For Multiple Indications
    • 4.6.4 Data Exclusivity for Biologic Drugs in the EU
    • 4.6.5 Naming of Biosimilars in the EU
    • 4.6.6 Biosimilar Substitution Not Allowed in the EU
    • 4.6.7 Latest Developments in EMEA Biosimilar Guidelines
    • 4.6.8 Future Development of EMEA Guidelines
  • 4.7 Progress Towards Development of ' Follow-On Protein Products' Regulatory Pathway in the US
    • 4.7.1 Lack of Biosimilar Regulatory Pathway in the US Restricted the Market
    • 4.7.2 Issues Affecting ' Follow-on Protein Products' Legislation in the US
    • 4.7.3 Progress in Development and Implementation of a Biosimilar Regulatory Pathway in the US, 2010
  • 4.8 Biosimilar Regulations in Japan
    • 4.8.1 Japanese Guidelines for Biosimilar Approvals, 2009
    • 4.8.2 Guidelines for the Development of a Biosimilar in Japan
    • 4.8.3 Filing a Biosimilar Application in Japan
    • 4.8.4 Naming of Biosimilars in Japan
  • 4.9 Economics of Biosimilar Development and Marketing
    • 4.9.1 Development of Biosimilars More Expensive than for Ordinary Generics
    • 4.9.2 Biosimilars Will Face Competition from Newer Branded Biologic Drugs
    • 4.9.3 Biosimilars Will Not Enjoy the Same Price Discount as Traditional Generics
    • 4.9.4 Opportunities for CROs and CMOs

5. Expert Opinions on the Sector

  • 5.1 Interview with Dr Donald L. Zuhn
    • 5.1.1 Latest Developments in Creating Regulatory Guidelines
    • 5.1.2 Period for Data Exclusivity
    • 5.1.3 When Will We See Biosimilars in the US?
  • 5.2 Interview with Dr Abul-Hassan
    • 5.2.1 Key Developments
    • 5.2.2 Which Biosimilars?
    • 5.2.3 Future Trends
    • 5.2.4 Data Exclusivity
  • 5.3 Interview with Dr Suzanne Sensabaugh
    • 5.3.1 Timescale of ' Follow-On Protein Product' Legislation
    • 5.3.2 The Most Important Factor Delaying ' Follow-on Protein Product' Legislation
    • 5.3.3 Prospects for Asian Biosimilars Manufacturers
    • 5.3.4 Prospects for Biosimilar Monoclonal Antibodies in the US
  • 5.4 Interview with Dr Rustom Mody
    • 5.4.1 Biosimilar Strategy
    • 5.4.2 Biosimilar Pipeline
    • 5.4.3 Biosimilar Monoclonal Antibodies
    • 5.4.4 Prospects for Indian CROs in Biosimilar R&D

6. Regional Biosimilar Markets

  • 6.1 Leading Biologic Drug Country Markets, 2009
  • 6.2 Asia' s Position in the World Biosimilars Market
  • 6.3 Regional Biosimilar Markets: Sales Prospects, 2010-2025
  • 6.4 The EU Biosimilar Market
    • 6.4.1 Regulation of Generic Pharmaceuticals in the EU
    • 6.4.2 Regulation of Biosimilars in the EU
    • 6.4.3 Biosimilar Approvals by the EMEA, 2006-2010
    • 6.4.4 European Biosimilar Market: Sales Forecast, 2010-2025
  • 6.5 The US Biosimilar Market
    • 6.5.1 Regulation of Biopharmaceuticals in the US
    • 6.5.2 No Regulatory Pathway for Biosimilars in the US
    • 6.5.3 FDA Has Already Approved a Number of ' Follow-On Protein Products'
    • 6.5.4 More-Complex ' Follow-On Protein Products' Must Bide Their Time
    • 6.5.5 US Biosimilar Market: Sales Forecast, 2010-2025
  • 6.6 The Japanese Biosimilar Market

7. The Biosimilars R&D Pipeline

  • 7.1 Competitive Landscape of the Biosimilars R&D Pipeline
    • 7.1.1 Leading Players in the Biosimilars Sector, 2010-2025
  • 7.2 Biocon
  • 7.3 Bioton/SciGen/BioPartners
    • 7.3.1 Gensulin/SciLin (Bioton/SciGen)
    • 7.3.2 Eutropin/Valtropin (LG Life Sciences/BioPartners)
    • 7.3.3 Alpheon (BioPartners)
  • 7.4 CinnaGen
  • 7.5 Cipla and Avesthagen
  • 7.6 Dr. Reddy' s Laboratories
  • 7.7 GTC Biotherapeutics and LFB Biotechnologies
  • 7.8 Hospira
  • 7.9 Intas and Apotex
  • 7.10 Merck & Co.
    • 7.10.1 Merck BioVentures
    • 7.10.2 Merck & Co.' s Glyco-Engineering Technology
    • 7.10.3 Insmed' s Biosimilars Acquired by Merck BioVentures
  • 7.11 Ranbaxy
  • 7.12 Sandoz
    • 7.12.1 Sandoz Pioneered Biosimilars in Europe
    • 7.12.2 Momenta and Sandoz Collaborate to Develop M-Enoxaparin and Other Biosimilars
  • 7.13 Shantha Biotechnics
  • 7.14 Stada
  • 7.15 Teva Pharmaceutical Industries
    • 7.15.1 Teva is a Biosimilar Early-Adopter
    • 7.15.2 Teva' s Joint Venture with Lonza

8. Conclusions

  • 8.1 The Biologic Drugs Market - Under-met Need for Lower-Cost Drugs
  • 8.2 Biosimilars are Not Generics
  • 8.3 The World Biosimilars Market in 2009
  • 8.4 Issues Slowing Down Adoption of Biosimilars
  • 8.5 World Biosimilar Market: Sales Forecast, 2010-2025
  • 8.6 Biosimilars and Follow-on Biologics - Summing Up Prospects

List of Tables

  • Table 2.1 Biologic Drug Types, 2009
  • Table 3.1 Leading Biologic Drug Types, 2009
  • Table 3.2 Blockbuster Biologics, 2009
  • Table 3.3 Leading Biosimilar Drug Types, 2009
  • Table 3.4 Biosimilar and Branded Biologics: World Market Shares and CAGR, 2009, 2015, 2020 & 2025
  • Table 3.5 World Biosimilar Market: Sales Forecast, 2010-2017
  • Table 3.6 World Biosimilar Market: Sales Forecast, 2018-2025
  • Table 3.7 Biosimilar Drug Types Market: World Sales Forecasts, 2010-2025
  • Table 3.8 Leading Monoclonal Antibody Brands, 2009
  • Table 3.9 The World Monoclonal Antibodies and AIFPs Market, 2009
  • Table 3.10 Biosimilar and Branded Monoclonal Antibodies & AIFPs: World Market Shares and CAGR, 2010, 2015, 2020 & 2025
  • Table 3.11 Biosimilar Monoclonal Antibodies & AIFPs: World Sales Forecast, 2009-2017
  • Table 3.12 Biosimilar Monoclonal Antibodies & AIFPs Market: World Sales Forecast, 2018-2025
  • Table 3.13 Leading Insulin Brands, 2009
  • Table 3.14 The World Insulin Market, 2009
  • Table 3.15 Biosimilar and Branded Insulin: World Market Shares and CAGR, 2010, 2015, 2020 & 2025
  • Table 3.16 Biosimilar Insulin Market: World Sales Forecast, 2009-2017
  • Table 3.17 Biosimilar Insulin Market: World Sales Forecast, 2018-2025
  • Table 3.18 The World Erythropoietin Market, 2009
  • Table 3.19 Biosimilar and Branded Erythropoietin: World Market Shares and CAGR, 2009, 2015, 2020 & 2025
  • Table 3.20 Biosimilar Erythropoietin Market: World Sales Forecast, 2009-2017
  • Table 3.21 Biosimilar Erythropoietin Market: World Sales Forecast, 2018-2025
  • Table 3.22 The World Interferon Market, 2009
  • Table 3.23 Biosimilar and Branded Interferons: World Market Shares and CAGR, 2009, 2015, 2020 & 2025
  • Table 3.24 Biosimilar Interferon Market: World Sales Forecast, 2009-2017
  • Table 3.25 Biosimilar Interferon Market: World Sales Forecast, 2018-2025
  • Table 3.26 The World CSF and IL-2 Drug Market, 2009
  • Table 3.27 Biosimilar & Branded CSF & IL-2 Drugs: World Market Shares & CAGR, 2009, 2015, 2020 & 2025
  • Table 3.28 Biosimilar CSF & IL-2 Drug Market: World Sales Forecast, 2009-2017
  • Table 3.29 Biosimilar CSF & IL-2 Drug Market: World Sales Forecast, 2018-2025
  • Table 3.30 The World Growth Hormones Market, 2009
  • Table 3.31 Biosimilar & Branded Growth Hormones: World Market Shares & CAGR, 2009, 2015, 2020 & 2025
  • Table 3.32 Biosimilar Growth Hormones Market: World Sales Forecast, 2009-2017
  • Table 3.33 Biosimilar Growth Hormones Market: World Sales Forecast, 2018-2025
  • Table 4.1 SWOT Chart for the Biosimilars Sector, 2010-2025
  • Table 4.2 Expected Patent Expiry Dates for Leading Biologic Drugs, 2010-2020
  • Table 6.1 Biologic Drugs: Regional Markets, 2009
  • Table 6.2 Biosimilars: Regional Markets, 2009
  • Table 6.3 Biosimilar Markets: Regional Sales Forecasts, 2010-2017
  • Table 6.4 Biosimilar Markets: Regional Sales Forecasts, 2018-2025
  • Table 6.5 Biosimilar Approvals by the EMEA, 2006-2010
  • Table 7.1 Pipeline Biosimilar Drugs: Part 1, 2010
  • Table 7.2 Pipeline Biosimilar Drugs: Part 2, 2010

List of Figures

  • Figure 3.1 Biologic Drug Types: World Market Shares, 2009
  • Figure 3.2 Biosimilar Drug Types: World Market Shares, 2009
  • Figure 3.3 Biosimilar Market: World Sales Forecast, 2010-2025
  • Figure 3.4 Biosimilar and Branded Biologics: World Market Shares, 2009, 2015, 2020 & 2025
  • Figure 3.5 Biosimilar Drug Types: World Market Shares, 2015
  • Figure 3.6 Biosimilar Drug Types: World Market Shares, 2020
  • Figure 3.7 Biosimilar Drug Types: World Market Shares, 2025
  • Figure 3.8 Leading Monoclonal Antibodies + AIFP Brands: World Market Shares, 2009
  • Figure 3.9 Biosimilar and Branded Monoclonal Antibodies & AIFPs: World Market Shares, 2010, 2015, 2020 & 2025
  • Figure 3.10 Biosimilar Monoclonal Antibodies & AIFP Market: World Sales Forecast, 2010-2025
  • Figure 3.11 Leading Insulin Brands: World Market Shares, 2009
  • Figure 3.12 Biosimilar and Branded Insulin: World Market Shares and CAGR, 2009, 2015, 2020 & 2025
  • Figure 3.13 Biosimilar Insulin Market: World Sales Forecast, 2010-2025
  • Figure 3.14 Leading Erythropoietin Brands, 2009
  • Figure 3.15 Biosimilar and Branded Erythropoietin: World Market Shares & CAGR, 2009, 2015, 2020 & 2020
  • Figure 3.16 Biosimilar Erythropoietin Market: World Sales Forecast, 2010-2025
  • Figure 3.17 Leading Interferon Brands, 2009
  • Figure 3.18 Biosimilar and Branded Interferons: World Market Shares & CAGR, 2009, 2015, 2020 & 2020
  • Figure 3.19 Biosimilar Interferons Market: World Sales Forecast, 2010-2025
  • Figure 3.20 Leading CSF and IL-2 Brands, 2009
  • Figure 3.21 Biosimilar & Branded CSF & IL-2 Drugs: World Market Shares, 2009, 2015, 2020 & 2025
  • Figure 3.22 Biosimilar CSF & IL-2 Drugs Market: World Sales Forecast, 2010-2025
  • Figure 3.23 Leading Growth Hormone Brands, 2009
  • Figure 3.24 Biosimilar & Branded Growth Hormones: World Market Shares, 2009, 2015, 2020 & 2025
  • Figure 3.25 Biosimilar Growth Hormones Market: World Sales Forecast, 2010-2025
  • Figure 6.1 Biologics Drugs: Regional Markets, 2009
  • Figure 6.2 Biosimilars: Regional Markets, 2009
  • Figure 6.3 Regional Biosimilar Market Shares, 2009, 2015, 2020 & 2025
  • Figure 6.4 European Biosimilar Market: Sales Forecast, 2010-2025
  • Figure 6.5 US Biosimilar Market: Sales Forecast, 2010-2025

Companies Listed

  • 3SBio
  • Abbott
  • Abraxis BioScience
  • Alexion Pharmaceuticals
  • Amgen
  • Amphastar Pharmaceuticals
  • Apotex
  • AstraZeneca
  • Avesta Biotherapeutics and Research (ABRPL)
  • Avesthagen
  • AxiCorp
  • Barr [acquired by Teva in 2008]
  • Bayer
  • Beijing Shuanglu
  • BIOCEUTICALS Arzneimittel
  • Biocon
  • Biogen Idec
  • BioPartners [acquired by Bioton in 2007]
  • Biotechnology Industry Organization (BIO) [US]
  • Bioton
  • Bristol-Myers Squibb
  • CCL Pharmaceuticals
  • CinnaGen
  • Cipla
  • CJ Corporation
  • CoGenesys [acquired by Teva in 2008]
  • CSL
  • CT Arzneimittel
  • Daiichi Sankyo
  • Dong-A
  • Dr. Reddy' s Laboratories
  • Eden Biodesign
  • Elan Corporation
  • Eli Lilly
  • European Committee for Medicinal Products for Human Use (CHMP)
  • European Medicines Agency (EMEA)
  • Feron
  • Food and Drug Administration (FDA) [US]
  • Fraunhofer Institute [Germany]
  • Genentech
  • Generic Pharmaceutical Association (GPhA) [US]
  • GeneScience Pharmaceutical
  • Getz Pharma
  • GlaxoSmithKline (GSK)
  • GTC Biotherapeutics
  • Halozyme Therapeutics
  • Hexal [acquired by Novartis in 2005]
  • Hospira
  • Hualida Biotech
  • Human Genome Sciences
  • Insmed
  • Intas Biopharmaceuticals
  • Ipsen Pharma
  • Johnson & Johnson
  • Kissei Pharmaceutical Co.
  • Kyowa Hakko Kirin
  • LFB Biotechnologies SASU
  • LG Life Sciences
  • Lonza Biologics
  • McDonnell Boehnen Hulbert & Berghoff LLP
  • Medice
  • Merck & Co.
  • Merck KGaA
  • Merck Serono
  • Merieux Alliance
  • Ministry of Health, Labour and Welfare (MHLW) [Japan]
  • Mitsubishi Tanabe Pharma Corporation
  • Momenta Pharmaceuticals
  • National Institute for Health and Clinical Excellence (NICE) [UK]
  • Novartis
  • Novo Nordisk
  • Office of Technology Commercialisation [New York, USA]
  • Pfizer
  • PrimaPharm
  • Qilu
  • Ranbaxy Laboratories
  • ratiopharm
  • Roche
  • Sandoz
  • sanofi-aventis
  • Schering-Plough
  • SciGen [subsidiary of Bioton]
  • Shantha Biotechnics
  • Sidus Pharmaceutical Group
  • Siegfried Biologics
  • Stada Pharmaceuticals
  • State Food and Drug Agency [China]
  • Teva Pharmaceutical Industries
  • Wockhardt
  • World Health Organization (WHO)
  • Wyeth Pharmaceuticals [now part of Pfizer]
  • Zenotech
Back to Top